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Several phase III studies (Quilty et al, 1982; Lewington et al,
1991; Porter et al, 1993; McEwan et al, 1994; Malmberg et al,
1997) now support the usefulness and cost effectiveness of Sr-89
either as an alternative or an adjunct to external beam radiotherapy
(EBRT) in men with bone pain due to metastatic prostate cancer.
Primary study end points have included pain response presented in
terms of reduction in severity and/or frequency of pain and/or
analgesic use, delayed onset of new painful sites and/or decrease
in EBRT requirement over the patient’s remaining lifetime. 
It is recognized that the effects of palliative treatment extend
beyond simply reducing the severity of a reference symptom, such
as pain. Health-related QoL describes a multidimensional view of
a patient’s psychological and social, as well as physical wellbeing.
Despite the frequent citing of the importance of overall QoL in
men with metastatic prostate cancer and the potential impact that
Sr-89 might have on QoL, there has been little attention paid to
formal evaluation of QoL as a primary end-point in the study of
Sr-89 to date. 
The Trans Canada Study Group (Porter et al, 1993) undertook a
limited QoL evaluation and found that in the areas of physical
mobility and pain control, Sr-89 produced a significant beneficial
effect for men with metastatic prostate cancer. This assessment, as
the authors acknowledge, was not ideal in that a standardized
instrument was not used and conclusions were based on data
pooled from a number of non-validated instruments including
linear analogue self assessment scales, questionnaires and patient
diaries. 
Following the establishment of a Government reimbursement in
early 1995, Sr-89 therapy for the relief of bone pain due to prostate
cancer became widely available in Australia. A group of interested
Radiation Oncologists (the Australian Metastron User’s Group)
took this opportunity to initiate a prospective study to (1) confirm
that treatment efficacy and toxicity were consistent with the world
literature and to (2) simultaneously assess the nature and time
course of any possible QoL benefits using a validated instrument.
Secondary end-points included toxicity, (specifically bone marrow
depression, pain ‘flare’ and/or other unexpected morbidity), and
PSA ‘response’ following Sr-89. 
MATERIALS AND METHODS 
This was a prospective multicentre study involving 13 oncology
centres in 5 states and territories of Australia. Accrual took place
over a two-year period from mid 1995 to mid 1997. There was a
minimum 8-month interval from the date of Sr-89 injection in the
last study patient to analysis, with a median follow up overall of
6.8 months (censoring patients at death). 
Eligible patients were those who had histologically proven
prostate cancer with bone scan evidence of metastatic disease and
who had progressed either clinically, biochemically or both
following ‘standard’ first-line hormone therapy (with or without
further hormonal manoeuvres), and who had one or more sites
of bony pain. 7 patients had previously been treated with various
chemotherapy agents as well. 
The protocol deliberately did not specify the exact indication for
the use of Sr-89 so as to reflect general clinical practice. However,
Sr-89 was not approved at that time for use as an adjunct to
external beam radiotherapy or for men with asymptomatic bone
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³100 ´ 109 l–1 and white cell counts ³3.5´ 109 l–1 prior to delivery
of Sr-89. Ethics committee approval was granted by involved
institutions and patients were required to provide written consent.
At registration, baseline QoL and pain evaluations were under-
taken. QoL was measured using the University of Manitoba,
Winnipeg, Functional Living Index – Cancer Instrument (FLIC),
Schipper, 1987. This is a well-validated, easily applied self-assess-
ment questionnaire incorporating multiple facets of psychosocial
state and sociability as well as parameters of physical well being
(Appendix B). Furthermore, this instrument was of particular
interest in that the validation studies of FLIC report lack of corre-
lation between traditional assessments of response, for example
improvement in pain, and other areas impacting on day-to-day
function such as mood and relationships with others. 
Pain was assessed jointly by physician and patient according
to the Radiation Therapy Oncology Group (RTOG) criteria
(Appendix A), (Tong et al, 1982). Analgesic requirements prior to
and after delivery of Sr-89 were recorded and used in conjunction
with pain scores to establish pain response over the time intervals
examined. Patients who had increase in analgesic requirements
were not scored as having pain improvement, regardless of RTOG
pain score status. 
Other baseline parameters including performance status, PSA at
recruitment, time since diagnosis of metastases, and extent of
skeletal disease (greater or less than 20 bone scan ‘hot spots’) were
recorded to allow correlation of these measures of disease status at
time of Sr-89 therapy with QoL responses. It was hypothesized
that patients who were earlier in the course of their metastatic
disease and/or with better performance status might benefit more
from Sr-89 than those who were not. In addition, it was postulated
that biochemical (PSA) changes, if still a useful surrogate for
disease activity in advanced disease, might parallel pain response. 
Patients received a single 150 MBq intravenous dose of Sr-89.
Follow up assessments of pain and QoL were conducted at
between two and three weeks following the injection and then
monthly if possible, until death. Toxicity, using WHO/EORTC
criteria for bone marrow suppression (Miller et al, 1981) and PSA
data were also recorded on these occasions. Where monthly visits
to the clinic were deemed inappropriate either on geographic or
medical grounds, then some information was collected by mailed
FLIC questionnaires and telephone conversations with patients or
carers. 
One patient was lost to follow up at the time of analysis. 8
patients had no post-treatment pain scores recorded (4) or response
data was only available beyond 3 months after Sr-89 (4). 11
patients had no follow-up QoL data collected. This left 85 patients
evaluable for pain response and 82 patients evaluable for QoL
analysis. 
The time intervals chosen for examination of QoL and pain
response were 0 to 6 weeks from Sr-89 (as any beneficial effect of
treatment would be expected to be seen well within this period), 6
weeks to 3 months (as most investigators report this as a median
period for maintaining pain response to radionuclide treatment)
and from 3 months to the time of death. The number of surviving
patients in the last time interval was too small to meaningfully
report results. 
Time to event (death) was measured from the day of the Sr-89
injection, with survival curves calculated using the method of
Kaplan and Meier (1958). For the follow up periods of 0 to 6
weeks and 6 weeks to 3 months, patients with multiple QoL
measures had their QoL scores averaged within individuals.
Factors considered as potentially influencing QoL changes
included ECOG performance status, number of hot spots and PSA
at baseline, as well as time from diagnosis of bone metastases and
pain response to therapy. Univariate and multivariate comparisons
were performed on these parameters using multiple linear regres-
sion and where appropriate multiple logistic regression analysis.
RESULTS 
Pain response 
Pain response to Sr-89 was categorized as complete, moderate or
minimal according to the RTOG pain scoring criteria (Appendix A).
Overall pain response (any reduction in RTOG pain score) over the
first 6 week and 6 week to 3 month periods taken together was 53
(62.4%) of 85 evaluable men. The degree of response is recorded
in Table 1. Complete relief of pain (no analgesics required) was
reported by 15 men (17.6%). 
Quality of life analysis 
The FLIC index was observed to increase by a median of 2.3
points in 61 evaluable patients over the first time period and 12.8
points from baseline in 55 evaluable patients in the second time
interval (6 weeks to 3 months). Examination of the possible influ-
ence of known prognostic factors is presented in the forest plots in
Figure 1. None of these ‘early metastatic disease’ parameters nor
performance status were found to statistically significantly relate
to better QoL gain. 
Patients achieving any pain response (minimal, moderate or
complete) were statistically significantly more likely to have
improvement in QoL on linear regression analysis (P = 0.013).
This relationship was sustained in a multivariate analysis adjusting
for factors that might confound changes in QoL index such as
measures of more advanced disease, as described, and poor perform-
ance status (P = 0.004). 
Toxicity 
In accordance with other investigators, pain ‘flare’ was defined as
a temporary increase in pain following injection of radionuclide
occurring between 0 and 14 days after the injection and lasting for
between 1 and 14 days. 35 out of 90 evaluable patients (39%) had
a flare, the majority occurring between 1 and 3 days following 
Sr-89 and lasting for 2 to 5 days. 
10 patients experienced bone marrow depression that presented a
clinical problem. One of these patients had oesophageal ulceration
which bled 3 weeks after Sr-89. 3 patients became tranfusion-
dependent and 7 others required at least one blood transfusion
following Sr-89. Despite protocol stipulations and recommended
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Table 1 Pain response over three months following Sr-89 
Pain response Number of patients % 
Complete 15 17.7 
Moderate 20 23.5 
Minimal 18 21.2 
Stable/worsening pain 32 37.7 
Denominator varies according to slightly different numbers of patients
evaluable within 6 week and 6 week to 3 month intervals. guidelines for the use of this agent, only 49 patients (53%) had
sequential white cell and platelet counts recorded following Sr-89. 6
of these (12% of evaluable patients) had post-treatment white cell
counts of grade 2 or worse on at least one occasion. 11 patients (22%
of evaluable patients) developed grade 2 or worse thrombocytopenia. 
12 patients (13%) reported nausea and/or vomiting (10) or
diarrhoea (2) which was felt by the treating physician and/
or patient to possibly be attributable to Sr-89. Gastrointestinal
disturbance occurred between 0 days and 2 weeks after injection
of Sr-89. 
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Figure 1A Changes in Quality of Life (FLIC) over the first six weeks (average in maximum difference from baseline with 95% confidence intervals). 
B Changes in Quality of Life (FLIC) between six weeks and three months (average in maximum difference from baseline with 95% confidence intervals). 
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QoL Points (B)Other adverse events included 7 cases of pathological fracture
during the course of the patients’ remaining lifetime. 10 patients
developed malignant spinal cord compression (MSCC) at some
time following injection of Sr-89. In none of these patients was
MSCC known to be imminent at the time of Sr-89 – a contra-
indication to the use of bone-seeking radiopharmaceutical. In 6 of
these men, MSCC occurred within three weeks of the injec-
tion. One patient developed an attack of gout 7 days following 
Sr-89. 
PSA response 
PSA ‘responders’ were defined according to the Trans Canada
Study (Porter and McEvan, 1993) as being those in whom the PSA
reduced at least 50% from the pre-treatment level. Depending on
the time point examined, between 32 and 37% of evaluable men
had PSA responses, thus defined, over 4 months following Sr-89,
beyond which numbers of patients became too small to meaning-
fully analyse. PSA response seen in this study is presented in
Figure 2 and is compared with the analogous Trans Canada results
of both the active (400MBq Sr-89) and placebo arms. Numbers
shown indicate the number of patients evaluable for assessment of
PSA response at each time point. 
Correlation of PSA responders and pain responders (of any
degree), using a Chi-squared analysis did not find a statistically
significant relationship between these two patient groups despite
an initial trend (P values for 0 to 6 week and 6 week to 3 month
intervals, 0.06 and 0.4 respectively). 
There was no overall survival difference seen between men who
had and those who did not have a PSA response. 
DISCUSSION 
The response rates to Sr-89 therapy of 62.5% (including 17.5%
complete responses) in this group of patients were typical of those
reported in phase III (Lewington et al, 1991; Porter et al, 1993a;
Quilty et al, 1994) and large phase II studies (Robinson et al, 1989;
Laing et al, 1991) in the literature. This is despite the relative ‘late’
use of this agent in this study as judged by the high median base-
line PSA (96 ng ml–1), high proportion of patients with extensive
skeletal disease (63% of 92 evaluable patients had more than 20
bone scan hot spots). 
Examination of the influence of prognostic factors on QoL
score improvement (Figure 1) reveals some interesting trends.
Whilst the confidence intervals are wide, the plots reveal that good
prognosis patients (better ECOG, low baseline PSA and low bone
scan load) tend to demonstrate larger increase in QoL score. This
observation is in keeping with Laing et al (1991) who reported that
a better analgesic effect was achieved with the administration of
Sr-89 whilst skeletal disease load was relatively low. The trend for
preferential benefit for good prognostic factors continued into the
second period. 
Although clinical experience and common sense suggest that
QoL should improve in patients having reduction in pain, physical
measures of response to therapies do not necessarily reflect their
overall benefit to the patient. Demonstrating that QoL improve-
ment really does accompany bone pain reduction following Sr-89
using objective testing is, therefore, important. In this study there
was strong correlation with improved QoL for the first 6 weeks
following Sr-89 therapy for patients in whom pain improved. This
relationship remained highly statistically significant controlling
for the above-mentioned indicators of more advanced metastatic
disease and performance status. 
The lack of demonstrable correlation between patients
achieving pain responses and those in whom PSA reduced to 50%
of its baseline level raises some points for contemplation. The
exact mechanism of action of Sr-89 remains unknown but the
results of this study would infer that the analgesic effect may be
achieved through action on reactive bone cells around metastases
or through effects mediated by other biological factors, rather than
through direct cancer cell kill. Further, these findings suggest that
either in this ‘late’ metastatic setting, PSA response is not a good
surrogate of overall disease activity, or rather (and more likely),
Sr-89 has a role in reduction of bone pain only without a substan-
tial influence on the disease process as a whole. 
On the other hand, the significant numbers of PSA ‘responses’
seen in this study, and in the Trans Canada Group report using Sr-
89 at a higher dose, suggest that there is some cytotoxic or
‘switching off’ effect of Sr-89 on malignant prostate cells. This
gives some support to the concept of a potential role for the earlier
application of this radionuclide in the situation of subclinical or
very early symptomatic metastatic disease, which was recently
under investigation in Europe. 
The toxicities recorded in this study point to the importance of
pre-and post-treatment monitoring for patients receiving Sr-89,
particularly in regard to bone marrow and neurological status. 
In summary, this study suggests that we do improve metastatic
prostate cancer patients’ overall QoL with the use of Sr-89 when
analgesic effect from this agent is achieved. As the current liter-
ature points to the advantage of early and adjunctive use of this
agent in men with bone pain from prostate cancer metastases, it is
beholden on clinicians treating these men to consider this therapy
at the appropriate point in the time-course of their disease. 
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(PSA response defined as at least 50% reduction in PSA from baseline –
numbers in brackets indicate numbers of PSA responders at each time point) REFERENCES 
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APPENDIX A: RTOG PAIN SCORING SYSTEM 
Pain score = product of severity and frequency. 
Pain severity Pain frequency
0 – no pain 0 – no pain 
1 – mild pain 1 – occasional (<once/day) 
2 – moderate pain 2 – intermittent (at least daily) 
3 – severe pain 3 – constant (most or all of the time) 
Pain responses
Minimal reliefa – pain score dropping below initial score 
Partial reliefa – pain score dropping to ≤4 
Complete relief – pain score dropping to 0 (no analgesics) 
aWithout significant increase in dose or type of analgesic. 
APPENDIX B: FLIC QUALITY OF LIFE QUESTIONNAIRE 
1. Most people experience some feelings of depression at times. Rate how often you get these feelings.
12 3456 78 9 1 0
Never Continually 
2. How well are you coping with your everyday stress?
12 3456 78 9 1 0
Not Well Very Well 
3. How much time do you spend thinking about your illness?
12 3456 78 9 1 0
Constantly Never 
4. Rate your ability to maintain your usual recreation or leisure activities.
12 3456 78 9 1 0
Able Unable 
5. Has nausea affected your daily functioning?
12 3456 78 9 1 0
Not At All A Great Deal 
6. How well do you feel today?
12 3456 78 9 1 0
Extremely Poor Extremely Well 302 SL Turner et al 
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7. Do you feel well enough to make a meal or do minor household repairs today?
12 3456 78 9 1 0
Very Able Not Able 
8. Rate the degree to which your cancer has imposed a hardship on the closest to you in the past two weeks.
12 3456 78 9 1 0
No Hardship Tremendous Hardship 
9. Rate how often you feel discouraged about your life.
12 3456 78 9 1 0
Always Never 
10. Rate your satisfaction with your work and your jobs around the house in the past month.
12 3456 78 9 1 0
Very Dissatisfied Very Satisfied 
11. How uncomfortable do you feel today?
12 3456 78 9 1 0
Not At All Very Uncomfortable 
12. Rate in your opinion, how disruptive your cancer has been to those closest to you in the past two weeks.
12 3456 78 9 1 0
Totally Disruptive No Disruption 
13. How much is pain or discomfort interfering with your daily activities?
12 3456 78 9 1 0
Not At All A Great Deal 
14. Rate the degree to which your cancer has imposed a hardship on you (personally) in the past two weeks.
12 3456 78 9 1 0
Tremendous Hardship No Hardship 
15. How much of your usual household tasks are you able to complete?
12 3456 78 9 1 0
All None 
16. Rate how willing you were to see and spend time with those closest to you in the past two weeks.
12 3456 78 9 1 0
Unwilling Very Willing 
17. How much nausea have you had in the past two weeks?
12 3456 78 9 1 0
None A Great Deal 
18. Rate the degree to which you are frightened of the future.
12 3456 78 9 1 0
Constantly Terrified Not Afraid 
19. Rate how willing you were to see and spend time with friends in the past two weeks.
12 3456 78 9 1 0
Unwilling Very Willing 
20. How much of your pain or discomfort over the past two weeks was related to your cancer?
12 3456 78 9 1 0
None All 
21. Rate your confidence in your prescribed course of treatment.
12 3456 78 9 1 0
No Confidence Very Confident 
22. How well do you appear today?
12 3456 78 9 1 0
Extremely Poor Extremely Well 
23. How would you rate your overall quality of life over the past two weeks?
12 3456 78 9 1 0
Life Couldn’t Be Worse Life Couldn’t Be Better 